ABSTRACT
Background: the use of beta-alanine (BA) to increase physical performance in the heavy-intensity domain zone (HIDZ) is widely documented. However, the effect of this amino acid on the post-exertion rating of perceived exertion (RPE), heart rate (HR), and blood lactate (BL) is still uncertain. Objectives: a) to determine the effect of acute BA supplementation on post-exertion RPE, HR, and BL in middle-distance athletes; and b) todetermine the effect of acute BA supplementation on physical performance on the 6-minute race test (6-MRT). Material and methods: the study included 12 male middle-distance athletes. The design was quasi-experimental, intrasubject, double-blind& crossover. It had two treatments (low-dose BA [30 mg·kg-1] and high-dose BA [45 mg·kg-1]) and a placebo, 72 hours apart. The effect of BA was evaluated at the end of the 6-MRT and post-exertion. The variables were RPE, HR and BL, and 6-MRT (m) distance. The statistical analysis included a repeated-measures ANOVA (p < 0.05). Results: the analysis evidenced no significant differences at the end of 6-MRT for all variables (p < 0.05). However, both doses of BA generated a lower post-exertion RPE. The high dose of BA caused significant increases in post-exertion BL (p < 0.05). Conclusion: acute supplementation with BA generated a lower post-exertion RPE. This decrease in RPE and the post-exertion BL increase could be related to an increase in physical performance in HIDZ. (AU)
Introducción: el uso de beta-alanina (BA) para aumentar el rendimiento físico en zonas con dominio de alta intensidad (HIDZ) está ampliamente documentado. Sin embargo, el efecto de este aminoácido sobre el índice de esfuerzo percibido (RPE), la frecuencia cardíaca (HR) y el lactato sanguíneo (BL) aún es incierto. Objetivos: a) determinar el efecto de la suplementación aguda de BA sobre el RPE, la HR y el BL posesfuerzo; y b) además del rendimiento en la prueba de carrera de 6 minutos (6-MRT), en atletas de media distancia. Material y métodos: el estudio incluyó a 12 atletas masculinos de media distancia. El diseño fue cuasiexperimental, intrasujeto, doble ciego y cruzado. Incluyó dos tratamientos (BA en dosis baja [30 mg·kg-1] y BA en dosis alta [45 mg·kg-1]) y placebo, con 72 horas de diferencia. El efecto de BA se evaluó al final de los 6-MRT y posesfuerzo. Las variables fueron RPE, HR y BL, y distancia en 6-MRT (m). El análisis estadístico incluyó un ANOVA de medidas repetidas (p < 0,05). Resultados: el análisis no evidenció diferencias significativas al final de los 6-MRT para todas las variables (p > 0,05). Sin embargo, ambasdosis de BA generaron un menor RPE posesfuerzo. La dosis alta de BA generó incrementos significativos en el BL posesfuerzo (p < 0,05). Conclusión: la suplementación aguda con BA generó un menor RPE posesfuerzo. Esta disminución del RPE y el aumento en el BL posesfuerzo podrían estar relacionados con un aumento del rendimiento físico en HIDZ. (AU)
Subject(s)
Humans , Male , Young Adult , Amino Acids/drug effects , Athletes , Athletic Performance , Sports Nutritional Physiological Phenomena , beta-Alanine/physiology , Non-Randomized Controlled Trials as TopicABSTRACT
Abstract Purpose: To investigate the effects of dexmedetomidine (DEX) on amino acid contents and the cerebral ultrastructure of rats with cerebral ischemia-reperfusion injury (I/R). Methods: Thirty-six, male, Wistar rats were randomly divided into three groups: the sham operation group (group C), the ischemia-reperfusion group (group I/R), and the DEX group (group D). The middle cerebral artery occlusion model was prepared by the modified Longa method. The time of ischemia was 180 min, and 120 min after reperfusion, the amount of glutamate (Glu), and γ-aminobutyric acid (GABA) in the brain were measured, and the ultrastructure-level changes in the cerebral cortex were examined using electron microscopy. Results: Compared to group C, Glu contents in group D, and I/R significantly increased. Compared to group I/R, Glu contents in group D significantly decreased. Compared to group C, GABA contents in group D, and I/R significantly increased, and those in group D significantly increased, as compared to group I/R. The cerebral ultrastructure was normal in group C. Vacuolar degeneration in the plastiosome and nervous processes, was more critical than in group D. Vascular endothelial cells (VEC) were damaged. On the contrary, these changes in group D significantly improved. Conclusion: Dexmedetomidine is capable of decreasing glutamergic content, and increasing GABAergic content, in order to decrease the injury of the cerebral ultrastructure, following cerebral ischemia-reperfusion injury.
Subject(s)
Animals , Male , Rats , Reperfusion Injury/metabolism , Cerebral Cortex/chemistry , Brain Ischemia/drug therapy , Neuroprotective Agents/pharmacology , Dexmedetomidine/pharmacology , Glutamine/metabolism , Cerebral Cortex/ultrastructure , Brain Ischemia/metabolism , Rats, Wistar , gamma-Aminobutyric Acid/drug effects , gamma-Aminobutyric Acid/metabolism , Amino Acids/drug effects , Amino Acids/metabolismABSTRACT
BACKGROUND/AIMS: Proton pump inhibitors (PPIs) act by irreversibly binding to the H+-K+-ATPase of the proton pump in parietal cells and may possibly affect the vacuolar H+-ATPase in osteoclasts. METHODS: We investigated the effect of 8 weeks of PPI treatment on the parameters of bone turnover and compared PPI with revaprazan, which acts by reversibly binding to H+-K+-ATPase in proton pumps. This study was a parallel randomized controlled trial. For 8 weeks, either a PPI or revaprazan was randomly assigned to patients with gastric ulcers. The parameters of bone turnover were measured at the beginning of and after the 8-week treatment period. RESULTS: Twenty-six patients (PPI, n=13; revaprazan, n=13) completed the intention-to-treat analysis. After the 8-week treatment period, serum calcium and urine deoxypyridinoline (DPD) were increased in the PPI group (serum calcium, p=0.046; urine DPD, p=0.046) but not in the revaprazan group. According to multivariate linear regression analysis, age > or =60 years was an independent predictor for the changes in serum calcium and urine DPD. CONCLUSIONS: In elderly patients, administering a PPI for 8 weeks altered bone parameters. Our study suggested that PPIs might directly alter bone metabolism via the vacuolar H+-ATPase in osteoclasts.